Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced the dosing of the first healthy volunteer in its randomized, double-blind, placebo-controlled, Phase I trial Debio 1453-101 (NCT07035769) ‘A First-in-Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of Debio 1453P in Healthy Adults’. Debiopharm's Debio ...

NIQ, a leading consumer intelligence company, is entering a strategic relationship with Decentriq to enable data collaboration for media use cases across Europe. Through the relationship, NIQ’s high quality consumer insights, including digital purchase data, will be available in Decentriq’s privacy-preserving clean rooms for the first time, enabling advertisers and agencies to utilize the data for audience profiling and closed loop measurement. Expanding beyond shopper insights NIQ is expan...

Almirall, S.A. (ALM) a global biopharmaceutical company dedicated to medical dermatology, is a major contributor to the 2025 European Academy of Dermatology and Venereology Congress (EADV) presenting new data across its broad portfolio of dermatological treatments including new real-world data of lebrikizumab on atopic dermatitis, new clinical data of tildrakizumab on psoriasis and tirbanibulin on actinic keratosis. The 34th EADV congress will take place from September 17 to 20 in Paris, France...

Chicago Atlantic announced its role as sole arranger and administrative agent in the funding of a senior secured term loan for TrueRC Canada Inc. (“TrueRC”). Founded by Hugo Chamberland in 2014, TrueRC is at the forefront of drone antenna design and manufacturing. “TrueRC’s reputation has been built on delivering high-quality products for both hobbyists and commercial applications alike. From drone racing enthusiasts to professional UAV operators, their antennas have become the trusted standa...